NCT05880758

Brief Summary

The goal of this clinical trial is to test the impact of repeated intermittent short sleep, with short sleep maintained 5 days per week followed by 2 days of prolonged sleep, compared to daily adequate sleep, on energy balance and cardiometabolic risk. A secondary goal of this research is to determine if maintaining a constant midpoint of sleep while undergoing intermittent short sleep, leads to better outcomes than intermittent short sleep with a 2-hour delay in sleep midpoint. The aims of this research will be tested in the context of a 3-group, parallel-arm, outpatient intervention of 4 weeks in duration, in young-to-middle-aged adults (aged 18-49 years).

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
72

participants targeted

Target at P50-P75 for not_applicable

Timeline
25mo left

Started Sep 2023

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress56%
Sep 2023Jun 2028

First Submitted

Initial submission to the registry

May 17, 2023

Completed
13 days until next milestone

First Posted

Study publicly available on registry

May 30, 2023

Completed
4 months until next milestone

Study Start

First participant enrolled

September 22, 2023

Completed
4.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2027

Expected
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2028

Last Updated

May 14, 2025

Status Verified

May 1, 2025

Enrollment Period

4.2 years

First QC Date

May 17, 2023

Last Update Submit

May 12, 2025

Conditions

Keywords

SleepCircadian RhythmsCardiometabolic Health

Outcome Measures

Primary Outcomes (5)

  • Fasting Plasma Glucose

    Insulin resistance will be assessed by measuring fasting plasma glucose levels.

    Up to 4 weeks

  • Insulin Level

    Insulin resistance will be assessed by measuring insulin levels.

    Up to 4 weeks

  • Morning Systolic and Diastolic Blood Pressure

    Ambulatory blood pressure will be measured.

    Up to 4 weeks

  • Evening Systolic and Diastolic Blood Pressure

    Ambulatory blood pressure will be measured.

    Up to 4 weeks

  • Fat mass

    Body composition will be measured using Dual-energy X-ray absorptiometry (DXA) to determine fat mass.

    Up to 4 weeks

Secondary Outcomes (14)

  • Low-density Lipoprotein (LDL) Level

    Up to 4 weeks

  • High-density Lipoprotein (HDL) Level

    Up to 4 weeks

  • Total Cholesterol Level

    Up to 4 weeks

  • Triglyceride Level

    Up to 4 weeks

  • C-reactive protein (CRP) Level

    Up to 4 weeks

  • +9 more secondary outcomes

Study Arms (3)

Stable Adequate Sleep (SAS)

ACTIVE COMPARATOR

Participants will go to bed and wake up at the same time every night, maintaining adequate sleep duration.

Behavioral: Sustained Adequate Sleep (SAS)

ISS_Alone

EXPERIMENTAL

Intermittent short sleep (ISS) 5 nights of 5.5 hours time in bed 2 nights of 9.5 hours time in bed with advanced bedtimes and delayed wake times

Behavioral: Intermittent Short Sleep (ISS)

ISS_SJL

EXPERIMENTAL

Intermittent short sleep with short jetlag (SJL) 5 nights of 5.5 hours time in bed 2 nights of 9.5 hours time in bed with constant bedtimes and delayed wake times

Behavioral: Intermittent Short Sleep (ISS)Behavioral: Social Jetlag (SJL)

Interventions

Restricted sleep duration of \<5.5 h/night for 5 nights (SR) followed by 2 nights of 9.5 hours of time in bed (TIB) (recover sleep) each week.

Also known as: ISS
ISS_AloneISS_SJL

2-hour delayed sleep timing.

Also known as: SJL
ISS_SJL

Goal of ≥7 hours of sleep/night with 8 hours of time in bed (TIB).

Also known as: SAS
Stable Adequate Sleep (SAS)

Eligibility Criteria

Age18 Years - 49 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Aged 18 to 49 years
  • BMI 20-29.9 kg/m2
  • Habitually sleeping 7-9 hours/night without sleep aids or naps

You may not qualify if:

  • Sleep disorders
  • Psychiatric disorders (including eating disorders) and seasonal affective disorder
  • Pregnancy (current/prior year)
  • Breastfeeding
  • Smokers (Any cigarette smoking or ex-smokers \<3years)
  • Diabetes
  • Elevated blood pressure, taking beta-blockers
  • Individuals taking anti-coagulants or anti-platelets
  • Recent weight change or participation in a weight loss program or have ever had bariatric surgery or other weight loss or gastrointestinal procedure.
  • Travel across time zones; shift work (non-traditional hours)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Columbia University Irving Medical Center

New York, New York, 10032, United States

RECRUITING

MeSH Terms

Conditions

Metabolic SyndromeObesity

Condition Hierarchy (Ancestors)

Insulin ResistanceHyperinsulinismGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesOverweightOvernutritionNutrition DisordersBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Marie-Pierre St-Onge, PhD

    Columbia University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Marie-Pierre St-Onge, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
Statistician will be blinded to intervention allocation; blinding of study participants is not possible due to the intervention type.
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Model Details: 3-arm, parallel study design
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

May 17, 2023

First Posted

May 30, 2023

Study Start

September 22, 2023

Primary Completion (Estimated)

December 1, 2027

Study Completion (Estimated)

June 1, 2028

Last Updated

May 14, 2025

Record last verified: 2025-05

Data Sharing

IPD Sharing
Will share

Data from this study will be available for sharing with other investigators. Data sharing requests should be made in writing and sent directly to the investigator(s) who generated the data. The purposes for using shared data should be stated in the request, and the data can only be used for research purposes. Data sharing agreements should be developed and accepted by both parties before data sharing takes place. Protecting the rights and privacy of human subjects and maintaining the study participants' confidentiality will be the first priority of our data sharing plan. HIPAA privacy rule for de-identification of a dataset will be followed before transferring data.

Shared Documents
STUDY PROTOCOL, SAP, ICF
Time Frame
Data will become available after results of the main aims from the final dataset have been accepted for publication.
Access Criteria
Contact PI for information on data availability and data sharing.

Locations